Global InformationZiltivekimab information
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | Interleukin 6 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| UNII |
|
| KEGG |
|
Ziltivekimab is a fully human monoclonal antibody against interleukin 6. It is developed by Novo Nordisk to treat heart failure. In clinical trials, levels of high-sensitivity C-reactive protein were reduced in people taking the drug.[1][2][3][4][5][6] The drug has also been tested in chronic kidney disease.[7]
- ^ Wada, Yukihiro; Jensen, Camilla; Meyer, Anna Sina Pettersson; Zonoozi, Amir Abbas Mohseni; Honda, Hirokazu (October 2023). "Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial". Journal of Cardiology. 82 (4): 279–285. doi:10.1016/j.jjcc.2023.05.006. PMID 37211246.
- ^ Adamstein, Nicholas H.; Cornel, Jan Hein; Davidson, Michael; Libby, Peter; de Remigis, Alessandra; Jensen, Camilla; Ekström, Kathrine; Ridker, Paul M (1 February 2023). "Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial". JAMA Cardiology. 8 (2): 177–181. doi:10.1001/jamacardio.2022.4277. PMC 9713672. PMID 36449307.
- ^ Pergola, Pablo E.; Devalaraja, Matt; Fishbane, Steven; Chonchol, Michel; Mathur, Vandana S.; Smith, Mark T.; Lo, Larry; Herzog, Kurt; Kakkar, Rahul; Davidson, Michael H. (January 2021). "Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial". Journal of the American Society of Nephrology. 32 (1): 211–222. doi:10.1681/ASN.2020050595. PMC 7894678. PMID 33272965.
- ^ Ridker, Paul M; Devalaraja, Matt; Baeres, Florian M M; Engelmann, Mads D M; Hovingh, G Kees; Ivkovic, Milana; Lo, Larry; Kling, Douglas; Pergola, Pablo; Raj, Dominic; Libby, Peter; Davidson, Michael (May 2021). "IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial". The Lancet. 397 (10289): 2060–2069. doi:10.1016/S0140-6736(21)00520-1. PMID 34015342. S2CID 235073253.
- ^ Wada, Y; Jensen, C; Meyer, S; Yamamoto, Y; Honda, H (3 October 2022). "Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial". European Heart Journal. 43 (Supplement_2). doi:10.1093/eurheartj/ehac544.2618.
- ^ Adamstein, N; Cornel, J; Davidson, M; Libby, P; De Remigis, A; Jensen, C; Rajan, S; Ridker, P (3 October 2022). "The effect of ziltivekimab on the neutrophil-lymphocyte ratio: analysis from RESCUE". European Heart Journal. 43 (Supplement_2). doi:10.1093/eurheartj/ehac544.2290.
- ^ Nowak, Kristen L.; Kakkar, Rahul; Devalaraja, Matt; Lo, Larry; Park, Wansu; Gobburu, Joga; Kling, Douglas; Davidson, Michael; Chonchol, Michel (February 2021). "A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD". Kidney360. 2 (2): 224–235. doi:10.34067/KID.0005862020. PMC 8741001. PMID 35373026.